Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | KCNA5 | P22460 | 4/20 | 0.33 |
| ▸ | CPB1 | P15086 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 3/20 | 0.30 |
| ▸ | RAB9A | P51151 | 3/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.30 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4139057 | 1.00 | POLB (0.34) | POLBCYP3A4CYP2C9CYP2C19KCNA5 | |
| SCHEMBL4139062 | 1.00 | POLB (0.34) | POLBCYP3A4CYP2C9CYP2C19KCNA5 | |
| SCHEMBL4697029 | 0.91 | CYP2C19 (0.34) | POLBCYP3A4CYP2C9CYP2C19KCNA5 | |
| SCHEMBL4697032 | 0.91 | CYP2C19 (0.34) | POLBCYP3A4CYP2C9CYP2C19KCNA5 | |
| SCHEMBL4697027 | 0.91 | CYP2C19 (0.34) | POLBCYP3A4CYP2C9CYP2C19KCNA5 | |
| SCHEMBL5187239 | 0.90 | POLB (0.33) | POLBCYP3A4CYP2C9CYP2C19KCNA5 | |
| SCHEMBL5187214 | 0.89 | CYP2C9 (0.36) | POLBCYP3A4CYP2C9CYP2C19KCNA5 | |
| SCHEMBL4146982 | 0.89 | ALDH1A1 (0.35) | POLBCYP3A4CYP2C9CYP2C19KCNA5 | |
| SCHEMBL4146984 | 0.89 | ALDH1A1 (0.35) | POLBCYP3A4CYP2C9CYP2C19KCNA5 | |
| SCHEMBL4146974 | 0.89 | ALDH1A1 (0.35) | POLBCYP3A4CYP2C9CYP2C19KCNA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090018329-A1 | NOVEL HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTIBACTERIALS AND BETA-LACTAMASE INHIBITORS | NOVEXEL (FR) | 2009-01-15 | — | — | US | disclosed |
| US-7439253-B2 | Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors | NOVEXEL (FR) | 2008-10-21 | — | — | US | disclosed |
| US-20040157826-A1 | Novel heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors | AVENTIS PHARMA S.A. (FR) | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157826-A1 | Novel heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors | GAA, ALPI, GANAB | POLB 387/4885CYP3A4 559/4885CYP2C9 251/4885 |
| US-20090018329-A1 | NOVEL HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTIBACTERIALS AND BETA-LACTAMASE INHIBITORS | GAA, GANAB, ALPI | POLB 319/4885CYP3A4 568/4885CYP2C9 273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.